Chemenu

Chemenu provides a wide variety of organic compounds and offers exclusive development for advanced intermediates.
#Chemotherapy
#medicineadvancedintermediates

[Chemenu @LinkchemL]

Casdatifan is a small molecule inhibitor of the oxygen-sensing transcription factor HIF-2⍺ that has demonstrated potent antitumor activity in xenograft models of renal cell cancer. Chemenu supplies novel building blocks https://t.co/7zoi521KMo

[Chemenu @LinkchemL]

XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.

[Chemenu @LinkchemL]

Nested’s lead program is NST-628, a non-degrading, molecular glue that targets multiple critical components in the RAS/MAPK pathway. Chemenu supplies novel building blocks https://t.co/6u8RRouRHe

[Chemenu @LinkchemL]

CervoMed’s Neflamapimod (VX-745) is p38α kinase inhibitor for the treatment of Dementia with Lewy Bodies (DLB) and may reverse synaptic dysfunction in the basal forebrain. Chemenu supports your scientific research and drug discovery.

[Chemenu @LinkchemL]

Pathalys pharma secures $105 million series B financing. Oversubscribed financing paves path to NDA submission and pre-commercialization efforts for upacicalcet. Upacicalcet can be used in SHPT to address an unmet need in the management of advanced CKD.

[Chemenu @LinkchemL]

Monlunabant is an oral, next generation small molecule CB1 receptor blockers with phase 2 obesity results expected in H2 2024. Chemenu supports your scientific research and drug discovery. Check our product catalog:  https://t.co/ZkTr7Zw36W

[Chemenu @LinkchemL]

IDRX-42 is a potent, oral, highly selective KIT inhibitor targeting all major categories of activating and resistance mutations in patients with KIT-mutant gastrointestinal stromal tumor (GIST) (including variants in exons 9, 11, 13 and 17).

[Chemenu @LinkchemL]

Enter Cenerimod, a novel, potent, and selective S1P1 receptor modulator featuring unique signaling properties, while notably negating broncho‐ and vasoconstrictor effects.

[Chemenu @LinkchemL]

Aptose’s Tuspetinib is a myeloid kinase inhibitor of SYK, FLT3, JAK1/2, RSK1/2, mutant KIT, and TAK1-TAB1 kinases. Tuspetinib is evaluated with azacitidine and venetoclax in 1L treatment for patients with ND AML unfit for chemotherapy.

[Chemenu @LinkchemL]

Bayer announced primary endpoint achieved in phase III FINEARTS-HF cardiovascular outcomes study investigating KERENDIA® (finerenone). Chemenu supplies novel building blocks https://t.co/wrp49i2sXj

[Chemenu @LinkchemL]

Pfizer’s Tinlorafenib (formerly PF-07284890) is a highly brain-penetrant inhibitor of BRAF V600-mutant tumors, and currently in a phase 1 clinical trial (NCT04543188).

[Chemenu @LinkchemL]

BioAge Labs presents preclinical data for apelin receptor agonist azelaprag for obesity demonstrating significant improvements in weight loss and body composition when combined with incretin drugs.

[Chemenu @LinkchemL]

Alpha Cognition’s oral therapy ZUNVEYL®(benzgalantamine) received FDA approval to treat Alzheimer’s disease. Chemenu supplies novel building blocks https://t.co/EKnovGkLkz

[Chemenu @LinkchemL]

Nocion Therapeutics presents data on preclinical and clinical development of Taplucainium, a novel, charged sodium channel blocker, as a potential treatment for chronic cough at the 13th London International Cough Symposium.

[Chemenu @LinkchemL]

Calico announced that ABBV-CLS-7262 (fosigotifator) for Vanishing White Matter disease has been selected for the FDA START pilot program. Chemenu supplies novel building blocks https://t.co/nqmYI5qR7W

[Chemenu @LinkchemL]

Kronos Bio’s KB-0742 enters into an expansion cohort with at a dose of 80mg given on a four-days-on, three-days-off schedule. Chemenu supplies novel building blocks https://t.co/ZKEYh0mdfr

[Chemenu @LinkchemL]

Sumitomo Pharma’s investigational menin inhibitor, DSP-5336 earns the FDA Fast Track Designation in relapsed or refractory acute myeloid leukemia with KMT2A rearrangements or NPM1 mutations. Chemenu supplies novel building blocks https://t.co/pK1hxF4sBA

[Chemenu @LinkchemL]

Bayer announced positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). Chemenu supplies novel building blocks https://t.co/J5yCuY5aP7

[Chemenu @LinkchemL]

60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.